



ANALGESIC NEPHROPATHY

RMA ID Number	Reference List for RMA028-03 as at April 2025
122290	Abbasi M, Teakell J (2023). Literature review: are NSAIDs harmful and is acetaminophen well tolerated? <i>Curr Opin Nephrol Hypertens</i> , 32(3): 284-9.
122279	Abdel Shaheed C, Ferreira GE, Dmitritchenko A, et al (2021). The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. <i>Med J Aust</i> , 214(7): 324-31.
122365	Abin-Carriquiry JA, Martínez-Busi M, Galvalisi M, et al (2018). Identification and quantification of cocaine and active adulterants in coca-paste seized samples: useful scientific support to health care. <i>Neurotox Res</i> , 34(2): 295-304.
79424	Alper AB (2015). Tubulointerstitial nephritis clinical presentation. Retrieved 7 September 2016, from http://emedicine.medscape.com/article/243597-clinical
125567	Anandan JV, Matzke GR (1981). Nephropathy as a hazard of analgesic abuse. <i>Am J Hosp Pharm</i> , 38(10): 1536-9. [Abstract]
78463	Anderson DM, Keith J, Novak PD (Lexicographers) (2012). Analgesic nephropathy. <i>Dorland's Illustrated Medical Dictionary</i> , 32nd Edition, 1241. Elsevier Saunders, Philadelphia.
45455	Anon (????). Study Group on Analgesics and Nephropathy (SAN). Retrieved 26 July 2007, from http://www.san-project.com
90500	Antoni S, Soerjomataram I, Moore S, et al (2014). The ban on phenacetin is associated with changes in the incidence trends of upper-urinary tract cancers in Australia. <i>Aust N Z J Public Health</i> , 38(5): 455-8.
123403	Appel RG, Bleyer AJ, McCabe JC (1995). Case report: analgesic nephropathy: a soda and a powder. <i>Am J Med Sci</i> , 310(4): 161-6.
122366	Arango-Merino L, Quevedo-Castro C, Mancera-Barros J, et al (2021). Cutting agents in cocaine: A temporal study of the period 2015-2017 in the Northern Region of Colombia. <i>Forensic Sci Int</i> , 327: 110911.
125572	Australian Industrial Chemicals Introduction Scheme (2016). CMR chemicals not registered under REACH: Human health tier II assessment. Retrieved 6 March 2025, from https://www.industrialchemicals.gov.au/
125568	Australian Medicines Handbook (2025). Aspirin (analgesic). Retrieved 6 March 2025, from https://amhonline.amh.net.au
125569	Australian Medicines Handbook (2025). Aspirin (antiplatelet). Retrieved 6 March 2025, from https://amhonline.net.au
121379	Australian Medicines Handbook (2024). NSAIDs. Retrieved 11 October 2024, from https://amhonline.amh.net.au/chapters/immunomodulators-anti-inflammatories/nsaids#nsaids-adverse
125789	Australian Medicines Handbook (2025). Ibuprofen. Retrieved 19 March 2025, from https://amhonline.amh.net.au/chapters/immunomodulators-anti-inflammatories/nsaids/ibuprofen

125788	Australian Medicines Handbook (2025). Search for 'phenacetin'. Retrieved 19 March 2025, from https://amhonline.amh.net.au/search?t=&q=phenacetin
125574	Australian Medicines Handbook (2024). Paracetamol. Retrieved 6 March 2025, from https://amhonline.net.au
44220	Bach PH, Nguyen TK (1998). Renal papillary necrosis--40 years on. <i>Toxicol Pathol</i> , 26(1): 73-91.
44379	Balasubramaniam J (2000). Selective COX-2 inhibitors and nephrotoxicity. <i>Am J Kidney Dis</i> , 36(3): 675-6.
44063	Barrett BJ (1996). Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. <i>Am J Kidney Dis</i> , 28(Suppl 1): S14-9.
78381	Beck LH, Salant DJ (2015). Tubulointerstitial diseases of the kidney. <i>Harrison's Principles of Internal Medicine</i> , 19th edition, Ch 340. McGraw Hill.
45464	Bennett WM, Feinstein AR et al (2001). [Comment] Relationship between nonphenacetin combined analgesics and nephropathy. <i>Kidney Int</i> , 60(5): 2039.
43969	Bennett WM, Porter GA (1998). Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. <i>J Nephrol</i> , 11(2): 70-5.
43957	Blowey DL (2005). Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. <i>Adolesc Med Clin</i> , 16(1): 31-43.
44066	Braden GL, O'Shea MH, Mulhern JG (2005). Core curriculum in nephrology. Tubulointerstitial diseases. <i>Am J Kidney Dis</i> , 46(3): 560-72.
122368	Broseus J, Gentile N, Esseiva P (2016). The cutting of cocaine and heroin: A critical review. <i>Forensic Sci Int</i> , 262: 73-83.
122266	Brune K, Renner B, Tiegs G (2015). Acetaminophen/paracetamol: A history of errors, failures and false decisions. <i>Eur J Pain</i> , 19(7): 953-65.
44065	Brunner FP, Selwood NH (1994). End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. <i>Nephrol Dial Transplant</i> , 9(10): 1371-6.
123602	Buettner M, Toennes SW, Buettner S, et al (2014). Nephropathy in illicit drug abusers: a postmortem analysis. <i>Am J Kidney Dis</i> , 63(6): 945-53.
399	Burrell JH, Yong JL, Macdonald GJ (1991). Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol. <i>Pathology</i> , 23(2): 107-14.
125194	Calello DP, Aldy K, Jefri M, et al (2022). Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose. <i>Clin Toxicol (Phila)</i> , 60(9): 1067-9.
44875	Campo A (2002). Acetaminophen, aspirin, and renal failure. <i>N Engl J Med</i> , 346(20): 1588-9; author reply 1588-9.
125571	Center for Forensic Research and Education (2021). Phenacetin: A toxic adulterant found in illicit street drugs. Retrieved 6 March 2025, from https://www.cfsre.org/
78382	Chang SH, Mathew TH, McDonald SP (2008). Analgesic nephropathy and renal replacement therapy in Australia: trends, comorbidities and outcomes. <i>Clin J Am Soc Nephrol</i> , 3(3): 768-76.
125195	Chapman CL, Hess HW, Lucas RA, et al (2021). Occupational heat exposure and the risk of chronic kidney disease of nontraditional origin in the United States. <i>Am J Physiol Regul Integr Comp Physiol</i> , 321(2): R141-51.
44874	Chogle AR (2003). Screening patients on long term non-steroidal anti-inflammatory drugs (NSAIDs) for nephrotoxicity--why necessary and how frequently? <i>J Assoc Physicians India</i> , 51: 1041-2.

125196	Conaghan PG, Arden N, Avouac B, et al (2019). Safety of paracetamol in osteoarthritis: what does the literature say? <i>Drugs Aging</i> , 36(Suppl 1): 7-14.
44054	Curhan GC, Knight EL, Rosner B, et al (2004). Lifetime nonnarcotic analgesic use and decline in renal function in women. <i>Arch Intern Med</i> , 164(14): 1519-24.
44069	Cuzzolin L, Dal Cere M, Fanos V (2001). NSAID-induced nephrotoxicity from the fetus to the child. <i>Drug Saf</i> , 24(1): 9-18.
125197	da Silva GO, de Araujo WR, Paixao TR (2018). Portable and low-cost colorimetric office paper-based device for phenacetin detection in seized cocaine samples. <i>Talanta</i> , 176: 674-8.
78045	De Broe ME (2015). Analgesic-related chronic kidney disease. Retrieved 27 April 2016, from http://www.uptodate.com/contents/analgesic-related-chronic-kidney-disease
78044	De Broe ME (2016). Clinical manifestations and diagnosis of analgesic nephropathy. Retrieved 27 April 2016, from http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-analgesic-nephropathy
125200	De Broe ME (2023). Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic misuse. Retrieved 18 February 2025, from https://www.uptodate.com/contents/urinary-tract-malignancy-and-atherosclerotic-disease-in-patients-with-chronic-analgesic-misuse
125198	De Broe ME (2024). Clinical manifestations and diagnosis of analgesic nephropathy. Retrieved 18 February 2025, from https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-analgesic-nephropathy
125199	De Broe ME (2024). Epidemiology and pathogenesis of analgesic-related chronic kidney disease. Retrieved 18 February 2025, from https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-analgesic-related-chronic-kidney-disease
78048	De Broe ME, Elseviers MM (2009). Over-the-counter analgesic use. <i>J Am Soc Nephrol</i> , 20(10): 2098-103.
123383	de Souza LM, Rodrigues RR, Santos H, et al (2016). A survey of adulterants used to cut cocaine in samples seized in the Espírito Santo State by GC-MS allied to chemometric tools. <i>Sci Justice</i> , 56(2): 73-9.
44067	Delzell E, Shapiro S (1998). A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. <i>Medicine (Baltimore)</i> , 77(2): 102-21.
44062	Delzell E, Shapiro S (1996). [Comment] Commentary on the National Kidney Foundation position paper on analgesics and the kidney. <i>Am J Kidney Dis</i> , 28(5): 783-5.
45283	Derby LE, Jick H (1991). Renal parenchymal disease related to over-the-counter analgesic use. <i>Pharmacotherapy</i> , 11(6): 467-71.
125201	Di Trana A, Berardinelli D, Montanari E, et al (2022). Molecular insights and clinical outcomes of drugs of abuse adulteration: new trends and new psychoactive substances. <i>Int J Mol Sci</i> , 23(23): 14619.
122283	Dua TK, Palai S, Roy A, et al (2022). Protective effect of probiotics against acetaminophen induced nephrotoxicity. <i>Mol Biol Rep</i> , 49(8): 8139-43.
44061	Duggin GG (1996). Combination analgesic-induced kidney disease: the Australian experience. <i>Am J Kidney Dis</i> , 28(Suppl 1): S39-47.
44378	Dunn MJ (2000). Are COX-2 selective inhibitors nephrotoxic? <i>Am J Kidney Dis</i> , 35(5): 976-7.
44068	Elseviers MM, De Broe ME (1999). Analgesic nephropathy. Is it caused by multi-analgesic abuse or single substance abuse? <i>Drug Saf</i> , 20(1): 15-24.

44374	Elseviers MM, De Broe ME (1997). Epidemiology of toxic nephropathies. <i>Adv Nephrol Necker Hosp</i> , 27: 241-62.
44226	Elseviers MM, De Broe ME (2001). [Comment] Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney Int</i> , 59(6): 2370, author reply 2372-3.
45465	Elseviers MM, De Schepper A, Corthouts R, et al (1995). High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. <i>Kidney Int</i> , 48(4): 1316-23.
44060	Elseviers MM, Waller I, Nenoy D, et al (1995). Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. <i>Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant</i> , 10(6): 808-14.
44375	Enck RE (2006). Opioid safety. <i>J Opioid Manag</i> , 2(4): 183.
44047	Eras J, Perazella MA (2001). NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? <i>Am J Med Sci</i> , 321(3): 181-90.
78384	Evans M, Forel CM, Bellocchio R, et al (2009). Acetaminophen, aspirin and progression of advanced chronic kidney disease. <i>Nephrol Dial Transplant</i> , 24(6): 1908-18.
45466	Feinstein AR, Heinemann LA, Curhan GC, et al (2000). Relationship between nonphenacetin combined analgesics and nephropathy: a review. <i>Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int</i> , 58(6): 2259-64.
45463	Forel CM, Ejerblad E, Lindblad P, et al (2001). Acetaminophen, aspirin, and chronic renal failure. <i>N Engl J Med</i> , 345(25): 1801-8.
125202	Forman JP (2024). Secondary factors and progression of chronic kidney disease. Retrieved 18 February 2025, from https://www.uptodate.com/contents/secondary-factors-and-progression-of-chronic-kidney-disease
44873	Fox JM (1996). [Comment] No proof for a particular role of combination analgesics causing end-stage renal failure. <i>Nephrol Dial Transplant</i> , 11(12): 2519-20.
45462	Fox JM (1999). [Comment] Doubts about a particularly high nephrotoxicity of combination analgesics. <i>Nephrol Dial Transplant</i> , 14(12): 2966-8.
44074	Fox JM, Siebers U (2003). Caffeine as a promoter of analgesic-associated nephropathy--where is the evidence? <i>Fundam Clin Pharmacol</i> , 17(3): 377-92.
44058	Gault MH, Barrett BJ (1998). Analgesic nephropathy. <i>Am J Kidney Dis</i> , 32(3): 351-60.
125203	Gault MH, Rudwal TC, Redmond NI (1968). Analgesic habits of 500 veterans: incidence and complications of abuse. <i>Can Med Assoc J</i> , 98(13): 619-26.
44129	Gooch K, Culleton BF, Manns BJ, et al (2007). NSAID use and progression of chronic kidney disease. <i>Am J Med</i> , 120(3): 280.e1-7.
44380	Graham MG (2001). Acute renal failure related to high-dose celecoxib. <i>Ann Intern Med</i> , 135(1): 69-70.
44376	Gupta K, Weber ML (2006). Renal effects of opioid exposure: considerations for therapeutic use. <i>J Opioid Manag</i> , 2(4): 236-40.
123442	Hampson HE, Li S, Walker DI, et al (2024). The potential mediating role of the gut microbiome and metabolites in the association between PFAS and kidney function in young adults: A proof-of-concept study. <i>Sci Total Environ</i> , 954: 176519.
406	Hartman GW, Torres VE, Leago GF, et al (1984). Analgesic-associated nephropathy. Pathophysiological and radiological correlation. <i>JAMA</i> , 251(13): 1734-8.

125204	Haruna I, Obeng-Gyasi E (2024). Association of combined per- and polyfluoroalkyl substances and metals with chronic kidney disease. <i>Int J Environ Res Public Health</i> , 21(4): 468.
45461	Heinemann LA, Garbe E, Lewis M, et al (2005). Case-control study on analgesics and nephropathy (SAN): protocol. <i>BMC Nephrol</i> , 6: 9.
125205	Hendry WF, Harrison AR, Kilpatrick FR (1972). Surgical management of renal papillary necrosis. <i>Proc R Soc Med</i> , 65(11): 1023-6.
44070	Henrich WL, Agodoa LE, Barrett B, et al (1996). Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. <i>Am J Kidney Dis</i> , 27(1): 162-5.
45460	Henrich WL, Clark RL, Kelly JP, et al (2006). Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: Report of the National Analgesic Nephropathy Study. <i>J Am Soc Nephrol</i> , 17(5): 1472-80.
125206	Hesse M, Thomsen KR, Thylstrup B, et al (2021). Purity of street-level cocaine across Denmark from 2006 to 2019: Analysis of seized cocaine. <i>Forensic Sci Int</i> , 329: 111050.
398	Hostetter TH, Brenner BM (1994). Tubulointerstitial diseases of the kidney. <i>Harrison's Principles of Internal Medicine</i> , 13th Edition, Chapter 242: 1314-5.
44219	Hoy WE (2006). Lessons in ethnoephrology. <i>Kidney Int</i> , 70(2): 251-7.
78383	IARC Working Group (2012). Phenacetin. <i>Pharmaceuticals. IARC Monographs on the evaluation of carcinogenic risks to humans, Vol100A</i> : 377-8.
65005	IARC Working Group (2012). Phenacetin. Vol 100A: 379-400. Retrieved 12 September 2012, from http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-25.pdf
44057	Ibanez L, Morlans M, Vidal X, et al (2005). Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. <i>Kidney Int</i> , 67(6): 2393-8.
78049	Ingrasciotta Y, Sultana J, Giorgianni F, et al (2015). Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. <i>PLoS One</i> , 10(4): e0122899.
78047	Izzedine H, Gueutin V (2016). Drug-induced chronic tubulointerstitial nephritis. Chapter 87. <i>Oxford Textbook of Clinical Nephrology</i> , 4th Edition, 695-7.
78043	Jaipaul N (2016). Analgesic nephropathy. Retrieved 27 April 2016, from https://www.msmanuals.com/en-au/professional/genitourinary-disorders/tubulointerstitial-diseases/analgesic-nephropathy
78380	Jaipaul N (2016). Tubulointerstitial nephritis. Retrieved 24 May 2016, from http://www.msmanuals.com/en-au/professional/genitourinary-disorders/tubulointerstitial-diseases/tubulointerstitial-nephritis
79033	Kankuri E, Solatunturi E, Vapaatalo H (2003). Effects of phenacetin and its metabolite p-phenetidine on COX-1 and COX-2 activities and expression in vitro. <i>Thromb Res</i> , 110(5-6): 299-303.
125209	Kannan L (2022). Renal manifestations of recreational drugs: A narrative review of the literature. <i>Medicine (Baltimore)</i> , 101(50): e31888.
79113	Kato H, Fujigaki Y, Inoue R, et al (2014). Therapeutic dose of acetaminophen as a possible risk factor for acute kidney injury: learning from two healthy young adult cases. <i>Intern Med</i> , 53(14): 1531-4.
125210	Katsuno T, Togo K, Ebata N, et al (2021). Burden of renal events associated with nonsteroidal anti-inflammatory drugs in patients with osteoarthritis and chronic low back pain: A retrospective database study. <i>Pain Ther</i> , 10(1): 443-55.

78050	Kelkar M, Cleves MA, Foster HR, et al (2012). Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims. <i>J Manag Care Pharm</i> , 18(3): 234-46.
78051	Khan YH, Sarriif A, Khan AH, et al (2014). Analgesic nephropathy: a neglected cause of chronic kidney disease. <i>J Appl Pharm Sci</i> , 4(8): 077-9.
125211	Kim JW (2023). Are nonsteroidal anti-inflammatory drugs safe for the kidney in ankylosing spondylitis? <i>J Rheum Dis</i> , 30(3): 139-45.
125208	Kim YM (2019). Comparing medical comorbidities between opioid and cocaine users: a data mining approach. <i>Addict Health</i> , 11(4): 223-33.
44075	Knights KM, Tsoutsikos P, Miners JO (2005). Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity. <i>Expert Opin Drug Metab Toxicol</i> , 1(3): 399-408.
125207	Koch B, Irvine AH, McIver JR, et al (1968). Renal papillary necrosis and abuse of analgesics. <i>Can Med Assoc J</i> , 98(1): 8-15.
125212	Koo BS, Hwang S, Park SY, et al (2023). The relationship between long-term use of nonsteroidal anti-inflammatory drugs and kidney function in patients with ankylosing spondylitis. <i>J Rheum Dis</i> , 30(2): 126-32.
44053	Kovacevic L, Bernstein J, Valentini RP, et al (2003). Renal papillary necrosis induced by naproxen. <i>Pediatr Nephrol</i> , 18(8): 826-9.
78379	Kuo HW, Tsai SS, Tiao MM, et al (2010). Analgesic use and the risk for progression of chronic kidney disease. <i>Pharmacoepidemiol Drug Saf</i> , 19(7): 745-51.
44055	Kurth T, Glynn RJ, Walker AM, et al (2003). Analgesic use and change in kidney function in apparently healthy men. <i>Am J Kidney Dis</i> , 42(2): 234-44.
123384	Laposchan S, Kranenburg RF, van Asten AC (2022). Impurities, adulterants and cutting agents in cocaine as potential candidates for retrospective mining of GC-MS data. <i>Sci Justice</i> , 62(1): 60-75.
125213	Lin PD, Cardenas A, Hauser R, et al (2021). Per- and polyfluoroalkyl substances and kidney function: Follow-up results from the Diabetes Prevention Program trial. <i>Environ Int</i> , 148: 106375.
44072	Lipton RB, Raskin N, Ruoff G, et al (1996). [Comment] Over-the-counter analgesics and kidney disease. <i>Am J Kidney Dis</i> , 27(6): 917-8.
125214	Lipworth L, Abdel-Kader K, Morse J, et al (2016). High prevalence of non-steroidal anti-inflammatory drug use among acute kidney injury survivors in the southern community cohort study. <i>BMC Nephrol</i> , 17(1): 189.
44224	Lipworth L, Friis S, Mellekjaer L, et al (2003). A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. <i>J Clin Epidemiol</i> , 56(8): 796-801.
78046	Longo DL, Fauci AS, Kasper DL, et al (2013). Renal tubular disease. <i>Harrison's Principles of Internal Medicine</i> , 18th Edition, Chapter 153. McGraw Hill.
44130	Lornoy W, Becaus I, Billioux JM, et al (2001). [Comment] Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney Int</i> , 59(6): 2371-2; author reply 2372-3.
44221	Lornoy W, Because I, Billioux JM, et al (1998). Analgesic nephropathy: clinical features and pathogenesis. Original data on the incidence and prevalence in a single renal unit. <i>Acta Clin Belg</i> , 53(5): 311-8.
125215	Ma C, Yu B, Zhang H, et al (2020). Non-Hodgkin's lymphoma in an elderly patient with renal dysfunction: a case report. <i>J Int Med Res</i> , 48(8): 300060520945858.
45457	Mackinnon B, Boulton-Jones M, McLaughlin K (2003). Analgesic-associated nephropathy in the West of Scotland: a 12-year observational study. <i>Nephrol Dial Transplant</i> , 18(9): 1800-5.

401	Mann JE, Goerig M, Brune K, et al (1993). Ibuprofen as an over-the-counter drug: is there a risk for renal injury? Clin Nephrol, 39(1): 1-6.
44073	Markowitz GS, Perazella MA (2005). Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta, 351(1-2): 31-47.
45038	McLaughlin JK, Lipworth L, Chow WH, et al (1998). Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int, 54(3): 679-86.
78385	Michielsen P (2007). In memoriam 'analgesic nephropathy' (circa 1972-2006). Nephrol Dial Transplant, 22(4): 999-1001.
43968	Michielsen P, De Schepper P (1998). Analgesic Nephropathy. N Engl J Med, 339(1): 48-9; author reply 50.
44071	Michielsen P, De Schepper P (1996). [Comment] Analgesic nephropathy in Belgium: confusion between prevalence and incidence. Am J Kidney Dis, 28(6): 958-9, Author reply 960-2.
78052	Michielsen P, Heinemann L, Mihatsch M, et al (2009). Non-phenacetin analgesics and analgesic nephropathy: clinical assessment of high users from a case-control study. Nephrol Dial Transplant, 24(4): 1253-9.
125566	Micromedex (2025). Acetaminophen. Retrieved 6 March 2025, from www.micromedexsolutions.com
125570	Micromedex (2025). Aspirin. Drugpoint summary. Retrieved 6 March 2025, from www.micromedexsolutions.com
125227	Micromedex (2025). Ibuprofen. Retrieved 19 February 2025, from https://www.micromedexsolutions.com/
125228	Micromedex (2025). Phenacetin. Retrieved 19 February 2025, from https://www.micromedexsolutions.com/
44372	Mihatsch MJ, Khanlari B, Brunner FP (2006). Obituary to analgesic nephropathy--an autopsy study. Nephrol Dial Transplant, 21(11): 3139-45.
125216	Miyauchi T, Marouka M, Nagayama T, et al (1990). [Carcinoma of the ureter after long-term use of analgesic [phenacetin derivative]--report of the two cases (spouses)]. Nihon Hinyokika Gakkai Zasshi, 81(12): 1908-11 [Article in Japanese].
400	Murray MD, Brater CD (1993). Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol, 33: 435-65.
402	Nanra RS (1993). Analgesic nephropathy in the 1990s - An Australian perspective. Kidney Int Suppl, 42: S86-92.
125573	Nanra RS (1976). Analgesic nephropathy. Med J Aust, 1(20): 745-8. [Abstract]
79114	Nanra RS (1980). Clinical and pathological aspects of analgesic nephropathy. Br J Clin Pharmacol, 10(Suppl 2): 359S-68.
44225	Nanra RS, Stuart-Taylor J, de Leon AH, et al (1978). Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int, 13(1): 79-92.
79115	National Institute of Diabetes and Digestive and Kidney Diseases (2007). Analgesic nephropathy (painkillers and the kidneys). U.S. Dept. of Health and Human Services Pub.
43966	Nelson EB (1995). [Comment] Kidney failure and analgesic drugs. N Engl J Med, 332(22): 1514-5; author reply 1515-6.
125217	Nielsen F, Fischer FC, Leth PM, et al (2024). Occurrence of major perfluorinated alkylate substances in human blood and target organs. Environ Sci Technol, 58(1): 143-9.
78053	Okafor UH, Unuigbo EI, Onwuchekwa AC, et al (2012). Analgesic nephropathy as a cause of end-stage renal disease in a 55 year-old Nigerian. Niger J Clin Pract, 15(2): 231-4.
47228	Ozkalemkas F, Ali R, Ozkan A, et al (2004). Tuberculosis presenting as immune thrombocytopenic purpura. Ann Clin Microbiol Antimicrob, 3: 16.

403	Paller MS (1990). Drug-induced Nephropathies. <i>Med Clin North Am</i> , 74(4): 909-17.
123405	Pan Y, Zhang L, Wang F, et al (2014). Status of non-steroidal anti-inflammatory drugs use and its association with chronic kidney disease: a cross-sectional survey in China. <i>Nephrology (Carlton)</i> , 19(10): 655-60.
44245	Parente F, Pastore L, Bargiggia S, et al (2007). Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. <i>Hepatology</i> , 45(5): 1267-74.
43970	Perazella MA (2003). Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. <i>Am J Med Sci</i> , 325(6): 349-62.
44059	Perazella MA (2005). Drug-induced nephropathy: an update. <i>Expert Opin Drug Saf</i> , 4(4): 689-706.
44377	Perazella MA, Eras J (2000). Are selective COX-2 inhibitors nephrotoxic? <i>Am J Kidney Dis</i> , 35(5): 937-40.
43965	Perneger TV, Whelton PK, Klag MJ (1994). Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i> , 331(25): 1675-9.
45458	Pinter I, Matyus J, Czegany Z, et al (2004). Analgesic nephropathy in Hungary: the HANS study. <i>Nephrol Dial Transplant</i> , 19(4): 840-3.
407	Pommer W, Bronder E, Greiser E, et al (1989). Regular analgesic intake and the risk of end-stage renal failure. <i>Am J Nephrol</i> , 9(5): 403-12.
44417	Pommer W, Greiser E (2001). Relationship between nonphenacetin-combined analgesics and nephropathy. <i>Kidney Int</i> , 59(6): 2372-3.
44222	Pospishil YO, Antonovych TM (1998). NSAIDs associated nephropathy. <i>Pol J Pathol</i> , 49(1): 35-9.
79425	Powell C (2014). Papillary necrosis. Retrieved 7 September 2016, from http://emedicine.medscape.com/article/439586-overview
125576	PubChem (2024). Acetaminophen. Retrieved 6 March 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Acetaminophen
125577	PubChem (2024). Aspirin. Retrieved 6 March 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Aspirin
125578	PubChem (2024). Ibuprofen. Retrieved 6 March 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Ibuprofen
125575	PubChem (2024). Phenacetin. Retrieved 6 March 2025, from https://pubchem.ncbi.nlm.nih.gov/compound/Phenacetin
404	Rahman A, Segasothy M, Samad SA, et al (1993). Analgesic use and chronic renal disease in patients with headache. <i>Headache</i> , 33(8): 442-5.
44223	Rastegar A, Kashgarian M (1999). Long-term analgesic use and renal disease. <i>Kidney Int</i> , 55(2): 743.
45459	Rexrode KM, Buring JE, Glynn RJ, et al (2001). Analgesic use and renal function in men. <i>JAMA</i> , 286(3): 315-21.
125218	Ribeiro M, Trevizol AP, Frajzinger R, et al (2019). Adulterants in crack cocaine in Brazil. <i>Trends Psychiatry Psychother</i> , 41(2): 186-190.
125219	Roberts E, Delgado Nunes V, Buckner S, et al (2016). Paracetamol: not as safe as we thought? A systematic literature review of observational studies. <i>Ann Rheum Dis</i> , 75(3): 552-9.
43967	Ronco PM, Flahault A (1994). Drug-induced end-stage renal disease. <i>N Engl J Med</i> , 331(25): 1711-2.
44049	Sandhu GK, Heyneman CA (2004). Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. <i>Ann Pharmacother</i> , 38(4): 700-4.
44052	Sandler DP, Burr FR, Weinberg CR (1991). Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. <i>Ann Intern Med</i> , 115(3): 165-72.
43964	Sandler DP, Smith JC, Weinberg CR, et al (1989). Analgesic use and chronic renal disease. <i>N Engl J Med</i> , 320(19): 1238-43. [Abstract]

405	Schaeffer AJ, Del Greco F (1992). Analgesic Nephropathy. PC Walsh, AB Retik, TA Stamey, ED Vaughan (ed). Campbell's Urology, 6th Edition, 2077-8. WB Saunders Co, Philadelphia.
44056	Schnuelle P, van der Woude FJ (2003). [Comment] Analgesics and renal disease in the postphenacetin era. Am J Kidney Dis, 42(2): 385-7.
45456	Schwarz S, Preuschhof L, Zellner D (1999). Incidence of analgesic nephropathy in Berlin since 1983. Nephrol Dial Transplant, 14(1): 109-12.
44048	Segasothy M, Chin GL, Sia KK, et al (1995). Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. Br J Rheumatol, 34(2): 162-5.
45387	Segasothy M (1993). Renal dysfunction and renal papillary necrosis with long-term use of NSAIDs as a sole or predominant analgesic: A new form of analgesic nephropathy. J Am Soc Nephrol, 4: 759.
44064	Segasothy M, Samad SA, Zulficar A, et al (1994). Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis, 24(1): 17-24.
125225	Si Y, Liu L, Zhang Y, et al (2024). Magnesium hydride protects against acetaminophen-induced acute kidney injury by inhibiting TXNIP/NLRP3/nf-kb pathway. Ren Fail, 46(1): 2330629.
44228	Siveke JT, Egert J, Sitter T, et al (2005). 5-ASA therapy and renal function in inflammatory bowel disease. Am J Gastroenterol, 100(2): 501.
122367	Solimini R, Rotolo MC, Pellegrini M, et al (2017). Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol, 18(7): 524-30.
124501	Stanifer JW, Stapleton HM, Souma T, et al (2018). Perfluorinated chemicals as emerging environmental threats to kidney health: a scoping review. Clin J Am Soc Nephrol, 13(10): 1479-92.
78054	Stefanovic V (2002). Analgesic nephropathy, Balkan endemic nephropathy and Chinese herbs nephropathy: separate tubulointerstitial kidney disease associated with urothelial malignancy. Med Biol, 9(1): 1-6.
125226	Steffens J, Nagel R (1988). Tumours of the renal pelvis and ureter. Observations in 170 patients. Br J Urol, 61(4): 277-83. [Abstract]
78773	Stonebridge P (2006). Surgery: an Oxford core text. 1.3 Colorectal and perianal disorders. Oxford University Press, 48.
124568	Teo SH, Tan NC, Choo JC, et al (2023). Non-steroidal anti-inflammatory drugs in chronic kidney disease and risk of acute adverse kidney events according to route of administration. Int Urol Nephrol, 55(3): 679-86.
125224	Urzola-Ortega J, Mendoza-Gomez L, Acevedo D (2021). Personal doses of cocaine and coca paste are adulterated in Cartagena de Indias (Colombia). ScientificWorldJournal, 2021: 5562315.
78055	van der Woude FJ, Heinemann LA, Graf H, et al (2007). Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol, 8: 15.
44227	Van Staa TP, Travis S, Leufkens HG, et al (2004). 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology, 126(7): 1733-9.
78056	Waddington F, Naunton M, Thomas J (2014). Paracetamol and analgesic nephropathy: Are you kidneying me? Int Med Case Rep J, 8: 1-5.
79116	Watanabe A, Fukami T, Takahashi S, et al (2010). Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab Dispos, 38(9): 1532-7.
44051	Whelton A (1999). Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med, 106(5B): 13S-24.
125223	White WB, Kloner RA, Angiolillo DJ, et al (2018). Cardiorenal safety of OTC analgesics. J Cardiovasc Pharmacol Ther, 23(2): 103-18.

44622	Whiting PH, Tisocki K, Hawksworth GM (1999). Human renal medullary interstitial cells and analgesic nephropathy. <i>Ren Fail</i> , 21(3-4): 387-92.
123438	Yang M, Zhao J, An Z, et al (2025). Role of per- and polyfluoroalkyl substances in the cardiorenal system: Unraveling crosstalk from the network of pollutants and phenotypes. <i>J Environ Sci (China)</i> , 150: 116-33.
123449	Yaxley J (2016). Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence. <i>Int J Risk Saf Med</i> , 28(4): 189-96.
125222	Yaxley J, Litfin T (2016). Non-steroidal anti-inflammatories and the development of analgesic nephropathy: a systematic review. <i>Ren Fail</i> , 38(9): 1328-34.
125220	Yun J, Jang EC, Kwon SC, et al (2023). The association of perfluoroalkyl substances (PFAS) exposure and kidney function in Korean adolescents using data from Korean National Environmental Health Survey (KoNEHS) cycle 4 (2018-2020): a cross-sectional study. <i>Ann Occup Environ Med</i> , 35: e5.
125193	Zhang X, Donnan PT, Bell S, et al (2017). Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. <i>BMC Nephrol</i> , 18(1): 256.